Ashvattha Therapeutics was founded by scientific leaders in nanomedicine and serial entrepreneurs who collectively have founded numerous startups.

The founders have raised over >$1B in capital though IPOs, and have advanced therapeutics from IND through to commercial launch. Together, the team is developing dendrimer drug conjugates across a diverse range of therapeutic areas.  We are also seeking collaborations with biopharma partners to enable the targeted delivery of their therapeutics.

Companies interested in discussing a collaboration with Ashvattha should contact Matt Brewer